Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
IMMU's Cash to Debt is ranked higher than
83% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. IMMU: No Debt )
IMMU' s 10-Year Cash to Debt Range
Min: 0.33   Max: No Debt
Current: No Debt

Equity to Asset 0.87
IMMU's Equity to Asset is ranked higher than
88% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. IMMU: 0.87 )
IMMU' s 10-Year Equity to Asset Range
Min: -0.58   Max: 0.92
Current: 0.87

-0.58
0.92
Interest Coverage No Debt
IMMU's Interest Coverage is ranked higher than
88% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. IMMU: No Debt )
IMMU' s 10-Year Interest Coverage Range
Min: 354.57   Max: 9999.99
Current: No Debt

354.57
9999.99
F-Score: 4
Z-Score: 39.84
M-Score: -4.14
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -620.56
IMMU's Operating margin (%) is ranked higher than
56% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. IMMU: -620.56 )
IMMU' s 10-Year Operating margin (%) Range
Min: -782.35   Max: 55.69
Current: -620.56

-782.35
55.69
Net-margin (%) -229.38
IMMU's Net-margin (%) is ranked higher than
61% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. IMMU: -229.38 )
IMMU' s 10-Year Net-margin (%) Range
Min: -782.35   Max: 60.72
Current: -229.38

-782.35
60.72
ROE (%) -28.33
IMMU's ROE (%) is ranked higher than
68% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. IMMU: -28.33 )
IMMU' s 10-Year ROE (%) Range
Min: -192.98   Max: 115.02
Current: -28.33

-192.98
115.02
ROA (%) -23.75
IMMU's ROA (%) is ranked higher than
69% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. IMMU: -23.75 )
IMMU' s 10-Year ROA (%) Range
Min: -79.19   Max: 80.21
Current: -23.75

-79.19
80.21
ROC (Joel Greenblatt) (%) -1475.42
IMMU's ROC (Joel Greenblatt) (%) is ranked higher than
60% of the 868 Companies
in the Global Biotechnology industry.

( Industry Median: -189.80 vs. IMMU: -1475.42 )
IMMU' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1475.42   Max: 784.03
Current: -1475.42

-1475.42
784.03
Revenue Growth (%) -57.80
IMMU's Revenue Growth (%) is ranked higher than
55% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -0.40 vs. IMMU: -57.80 )
IMMU' s 10-Year Revenue Growth (%) Range
Min: -57.8   Max: 83.3
Current: -57.8

-57.8
83.3
» IMMU's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

IMMU Guru Trades in

IMMU Guru Trades in

Q3 2013

IMMU Guru Trades in Q3 2013

Jim Simons 260,207 sh (New)
Steven Cohen 1,810,000 sh (New)
» More
Q4 2013

IMMU Guru Trades in Q4 2013

Paul Tudor Jones 18,678 sh (New)
Jim Simons Sold Out
Steven Cohen 1,398,548 sh (-22.73%)
» More
» Details

Insider Trades

Latest Guru Trades with IMMU



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 12.00
IMMU's P/B is ranked lower than
65% of the 787 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. IMMU: 12.00 )
IMMU' s 10-Year P/B Range
Min: 4.32   Max: 249
Current: 12

4.32
249
P/S 34.00
IMMU's P/S is ranked lower than
71% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 10.38 vs. IMMU: 34.00 )
IMMU' s 10-Year P/S Range
Min: 2.97   Max: 103
Current: 34

2.97
103
EV-to-EBIT 250.00
IMMU's EV-to-EBIT is ranked lower than
83% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. IMMU: 250.00 )
IMMU' s 10-Year EV-to-EBIT Range
Min: 5.8   Max: 175.5
Current: 250

5.8
175.5

Valuation & Return

vs
industry
vs
history
Price/Net Cash 15.37
IMMU's Price/Net Cash is ranked lower than
59% of the 476 Companies
in the Global Biotechnology industry.

( Industry Median: 9.10 vs. IMMU: 15.37 )
IMMU' s 10-Year Price/Net Cash Range
Min: 5.36   Max: 218.75
Current: 15.37

5.36
218.75
Price/Net Current Asset Value 14.31
IMMU's Price/Net Current Asset Value is ranked lower than
57% of the 520 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. IMMU: 14.31 )
IMMU' s 10-Year Price/Net Current Asset Value Range
Min: 5.13   Max: 462.5
Current: 14.31

5.13
462.5
Price/Tangible Book 12.21
IMMU's Price/Tangible Book is ranked lower than
66% of the 727 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. IMMU: 12.21 )
IMMU' s 10-Year Price/Tangible Book Range
Min: 3.08   Max: 96
Current: 12.21

3.08
96
Price/Median PS Value 1.34
IMMU's Price/Median PS Value is ranked higher than
58% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. IMMU: 1.34 )
IMMU' s 10-Year Price/Median PS Value Range
Min: 0.12   Max: 7.88
Current: 1.34

0.12
7.88
Earnings Yield (Greenblatt) 0.40
IMMU's Earnings Yield (Greenblatt) is ranked lower than
73% of the 379 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. IMMU: 0.40 )
IMMU' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.6   Max: 17.4
Current: 0.4

0.6
17.4
Forward Rate of Return (Yacktman) -0.64
IMMU's Forward Rate of Return (Yacktman) is ranked higher than
86% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. IMMU: -0.64 )
IMMU' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -10   Max: 0.1
Current: -0.64

-10
0.1

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:IM3.Germany
Immunomedics, Inc., was incorporated in Delaware in 1982. It is a biopharmaceutical company which develops monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. It has developed advanced proprietary technologies that allow it to create humanized antibodies that can be used either alone in unlabeled or 'naked' form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins, in each case to create targeted agents. Using these technologies, it has built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. Its product candidate, epratuzumab, is currently in two Phase III clinical trials in lupus. In oncology, the Company is planning to launch a Phase III pivotal trial for clivatuzumab labeled with a radioisotope in pancreatic cancer patients. Other solid tumor therapeutics in Phase II clinical development includes 2 antibody-drug conjugates; labetuzumab-SN-38 (IMMU-130) and hRS7-SN-38 (IMMU-132).It also have a majority ownership in IBC Pharmaceuticals, Inc., which is developing a DOCK-AND-LOCK (DNL) method with for making fusion proteins and multifunctional antibodies. DNL is being used particularly to make bispecific antibodies targeting cancers and infectious diseases as a T-cell redirecting immunotherapy, as well as bispecific antibodies for next-generation cancer and autoimmune disease therapies. It has licensed its product candidate, epratuzumab, to UCB S.A., or UCB, for the treatment of all non-cancer indications worldwide. Epratuzumab's advanced clinical testing is for the treatment of systemic lupus erythematosus, or SLE (lupus), in non-Hodgkin lymphoma, or NHL and acute lymphoblastic leukemia, or ALL. During the 2013 fiscal year, it have completed a Phase Ib clinical trial evaluating clivatuzumab tetraxetan (hPAM4) labeled with yttrium-90, or Y-90, with and without low-dose gemcitabine, in pancreatic cancer patients who had received at least 2 prior therapies. It also initiated a randomized Phase Ib study examining the Y-90-labeled clivatuzumab tetraxetan, with and without low-dose gemcitabine, in pancreatic cancer patients who have received at least 2 prior therapies. It is also conducting a National Cancer Institute, or NCI, grant-supported study combining unlabeled veltuzumab with Y-90-labeled epratuzumab tetraxetan in patients with diffuse large B-cell lymphoma, or DLBCL, the aggressive form of NHL. The second ADC in its product pipeline is, labetuzumab-SN-38, which is in a Phase I/II trial in patients with advanced colorectal cancer. In the first half of fiscal 2013, it plan to begin a new study examining the safety and tolerability of its third ADC, hRS7-SN-38, in patients with solid cancers, for which an Investigational New Drug (IND) application has been filed with the Food and Drug Administration (FDA). The Company competes with Biogen Idec, Roche, GlaxoSmithKline, Seattle Genetics, Merck Sero

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide